SEC Company Response from Brickell Biotech, Inc. (FRTX) (CIK 0000819050) — Oct 20, 2020
Brickell Biotech, Inc. (FRTX) (CIK 0000819050)
Date: Oct. 20, 2020 · CIK: 0000819050 · Accession: 0000819050-20-000211
AI Filing Summary & Sentiment
File numbers found in text: 333-249441
Letter
Re: Brickell Biotech, Inc.
Document
October 20, 2020
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1
File Number 333-249441
Ladies and Gentlemen:
Brickell Biotech, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement be accelerated so that it will become effective at 4:00 p.m. Eastern time on October 22, 2020, or as soon thereafter as practicable.
Please telephone the undersigned (305-582-4657) or Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP (612-766-8419) if you have any questions with respect to the foregoing.
Very truly yours,
BRICKELL BIOTECH, INC.
Show Raw Text
CORRESP
1
filename1.htm
Document
October 20, 2020
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Brickell Biotech, Inc.
Registration Statement on Form S-1
File Number 333-249441
Ladies and Gentlemen:
Brickell Biotech, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement be accelerated so that it will become effective at 4:00 p.m. Eastern time on October 22, 2020, or as soon thereafter as practicable.
Please telephone the undersigned (305-582-4657) or Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP (612-766-8419) if you have any questions with respect to the foregoing.
Very truly yours,
BRICKELL BIOTECH, INC.
By: /s/ Andrew Sklawer
Name: Andrew Sklawer
Title: Chief Operating Officer